Clinical Trial Update: A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH) [EARLY_Phase 1]

View source ↗

Summary

This early Phase 1 trial assessed immunogenicity and oral tolerance to Keyhole Limpet Hemocyanin (KLH) in autoimmune diseases. The study was terminated, and res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Diseases

Drugs mentioned

• Keyhole Limpet Hemocyanin (Keyhole limpet hemocyanin)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Autoimmune Disorders | EARLY_Phase 1 | Status: TERMINATED | Results posted: 2016-04-12